30 results about "HLA-DRB1" patented technology

The invention discloses a human leukocyte antigen HLA-A and HLA-B gene full-length sequencing method and an HLA gene sequencing and typing method. The HLA-A and HLA-B gene full-length sequencing method comprises the following steps of: a, performing PCR amplification on about 4kb full-length sequences of HLA-A and HLA-B genes by using a pair of primers respectively; and b, cloning the amplification products to a pGEM-Tea sy vector, sequencing the full-length sequences by using ten walking sequencing primers in positive and negative directions respectively, and totally obtaining 38 allele 4.3kb full-length sequences of the HLA-A and 30 allele 3.7kb full-length sequences of the HLA-B. The HLA-A and HLA-B sequencing and typing method comprises the following steps of: performing PCR amplification on typing target areas of the HLA-A and HLA-B by using two pairs of primers respectively; and performing two directional sequencing on products by using fourteen sequencing primers respectively, wherein the HLA-DRB1 and HLA-DQB1 sequencing and typing method comprises the following steps of: amplifying sequences of second and third exons of DRB1 and DQB1 by adopting group specificity primers respectively; performing two directional sequencing on the second and third exons of the DRB1 by adopting eight group specificity primers and three sequencing primers; and performing two directional sequencing on the second and third exons of the DQB1 by adopting four sequencing primers respectively.

Provided is a method for evaluating a drug anaphylactic reaction caused by antiepileptic drug phenytoin with HLA allele. The drug anaphylactic reaction comprises a Steven Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) or a drug reaction with eosinophiliaand systemic symptoms (DRESS). The gene polymorphism (including CYP2C9, CYP2C19, CYP2C8 and CYP2C18) of CYP2C genes, HLA gene types (including HLA-A*0207, HLA-A*2402, HLA-B*1301, HLA-B*1502, HLA-B*4001, HLA-B*4609, HLA-B*5101, HLA-DRB1*1001 and HLA-DRB1*1502) and the concentration of phenytoin in plasma of a patient all may cause phenytoin adverse drug reactions.

The invention provides a kit for detecting HLA genotypes through fluorescent PCR melting curve assay. The kit includes HLA-A, HLA-B, HLA-DRB1 and HLA-DQB1 genotypes, amplification is performed by using a 96-pore optical reaction plate containing primers, an amplified dual-strand DNA product is actively bonded through SYBR Green I, the low-resolution genotypes of HLA-A, HLA-B, HLA-DRB1 and HLA-DQB1 are comprehensively judged according to the result of a 96-pore fusion curve, and accordingly diagnosis of the matched types for organ transplantation is assisted.

Disclosed are: a method for activating a helper T cell, which comprises the step of adding a WT1 peptide to an antigen-presenting cell to activate the helper T cell, wherein the WT1 peptide is capable of binding to any one selected from an HLA-DRB1<*>1501 molecule, an HLA-DPB1<*>0901 molecule and an HLA-DPB1<*>0501 molecule; a composition for use in the method; a therapeutic and / or prophylactic method for cancer by activating a helper T cell; a pharmaceutical composition for use in the therapeutic and / or prophylactic method; and others.

The invention discloses a Juno<TM>-based safety medication detection kit for children and a chip. The kit and the chip comprise primers at the following loci: HLA-DRB1*15:01-DQB1*06:02 loci of an HLAgene, an HLA-B*57:01 locus of the HLA gene, an HLA-B*15:02 locus of the HLA gene, an HLA-B*58:01 locus of the HLA gene, a rs267606617 locus of an MT-RNR1 gene,a rs267606618 locus of the MT-RNR1 gene,a rs267606619 locus of the MT-RNR1 gene, a rs1057910 locus of a CYP2C9 gene, a rs4244285 locus of a CYP2C19 gene, a rs4986893 locus of the CYP2C19 gene, a rs1065852 locus of a CYP2D6 gene, and a rs2242480 locus of a CYP3A4 gene.

The invention relates to a gene detection method and kit capable of being used for clinical detection. The method is aimed at HLA-DRB1*03 low-resolution gene and can realize accurate, rapid, simple and inexpensive detection, and can be used for providing important information for treatment and prognosis of clinically relevant diseases such as recurrent laryngeal papilloma and the like.

A method for determining immunogenicity of a protein agent. The method includes constructing a library of peripheral blood mononuclear cells having various HLA-DRB1 genotypes; culturing peripheral blood mononuclear cell CD14+ monocyte-derived immature dendritic cells for each genotype in a medium containing a protein to be measured, GM-CSF, IL-4, TNF-α, IL-1β, IL-6 and PGF2 to prepare mature dendritic cells; removing CD8+ T cells from the peripheral blood mononuclear cells for each genotype to prepare CD8+ T cell-free peripheral blood mononuclear cells; co-culturing the mature dendritic cells and the CD8+ T cell-free peripheral blood mononuclear cells at a cell count ratio of approximately 1:5 to 1:20; and quantifying the CD4+ T cells proliferated by co-cultivation per genotype.

The invention discloses application of an HLA (human leukocyte antigen) gene to judging white vulval lesions of Chinese han-nationality women, and belongs to the field of gynaecology and immunological genetics. The susceptible population of vulvar lichen sclerosus and vulvar squamous cell hyperplasia is judged by detecting and screening a susceptibility gene and a resistance gene through the HLA gene, and control study and judgment analysis are performed by observing conditions of alleles of HLA-B*5, HLA-DRB1*12, HLA-B*40, HLA-A*11, HLA-A*31, HLA-B*13, HLA-B*35, HLA-DRB1*01 and HLA-DRB1*03 of vulvar lichen sclerosus and vulvar squamous cell hyperplasia patients. The application is of important guiding significance on early-stage diagnosis, predication, prevention and treatment of vulvar dystrophy.

The invention discloses application of HLA-DRB1*04:03 allele to evaluation of risk of occurrence of drug eruption caused by methimazole, discloses application of a material for detecting the HLA-DRB1*04:03 allele to preparation of a kit and also discloses a kit comprising the material for detecting the HLA-DRB1*04:03 allele. The kit has the functions of (a) evaluating the risk of occurrence of drug eruption caused by methimazole of testees, (b) evaluating the risk of occurrence of drug eruption caused by methimazole of the testees and showing that the risk of occurrence of drug eruption of thetestees carrying the HLA-DRB1*04:03 allele after taking methimazole is higher than that of the testees without carrying the HLA-DRB1*04:03 allele, (c) evaluating whether the testees are suitable fortaking methimazole and (d) evaluating whether the testees are suitable for taking methimazole and showing that the testees carrying the HLA-DRB1*04:03 allele are not suitable for taking methimazole.